CRISPR-based genome editing has accelerated biological research and offers immense potential for studying and treating human diseases. The CRISPR-Cas9 system requires a Cas9 nuclease and a guide RNA, which can consist of either a CRISPR RNA (crRNA) coupled with a trans-activating crRNA (tracrRNA), or a single guide RNA (sgRNA) which combines the crRNA and tracrRNA in a single molecule. Both guide RNA formats can be chemically synthesized, offering advantages over expression systems.
In this webinar, sponsored by Horizon Discovery, Dr. James Goldmeyer will explain how synthetic guide RNAs are amenable to chemical modifications for increased stability, eliminate time-consuming steps of cloning and sequencing, and do not provoke the inherent immune response and cytotoxicity of in vitro transcribed guide RNAs. Goldmeyer will also outline how synthetic guide RNAs can be readily delivered into cells for high-throughput arrayed screening applications and expand the types of phenotypic readouts to high-content and morphology-based assays.
This webinar will cover:
- The development and application of Horizon Edit-R Synthetic sgRNA reagents for gene-specific CRISPR knockout
- The functionality and performance of synthetic guide RNAs in several different cell models, including primary T cells
- How synthetic guide RNAs provide robust functional gene knockout and further simplify high-throughput loss-of-function screening
Friday, March 12 - 4:00 PM